AIA
ANIP icon

Avalon Investment & Advisory’s ANI Pharmaceuticals ANIP Stock Holding History

Avalon Investment & Advisory’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-48,153
Closed -$3.22M – 348
2018
Q2 		$3.22M Buy
48,153
+4,040
+9% +$252K 0.1% 183
2018
Q1 		$2.57M Buy
+44,113
New +$2.8M 0.08% 190

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Avalon Investment & Advisory's ANIP Position: Q3 2018 in Review

Avalon Investment & Advisory sold out of ANI Pharmaceuticals (ANIP) in Q3 2018, closing a stake of 48,153 shares — an estimated $3.22M sold.

Avalon Investment & Advisory first reported a position in ANIP in Q1 2018 and held it in 2 quarters. The position peaked at $3.22M in Q2 2018. 173 funds tracked by Wall St. Rank hold ANIP as of Q3 2018.

  • Avalon Investment & Advisory reported no remaining ANI Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Avalon Investment & Advisory sold 48,153 ANI Pharmaceuticals shares in Q3 2018, an estimated $3.22M.
  • Avalon Investment & Advisory first reported a position in ANI Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Avalon Investment & Advisory's ANI Pharmaceuticals position peaked at $3.22M in Q2 2018.
  • 173 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2018.

Based on Avalon Investment & Advisory's 13F filing for Q3 2018, filed 14 Nov 2018.